Show simple item record

dc.contributor.authorChiappini, Stefania
dc.contributor.authorMosca, Alessio
dc.contributor.authorMartinotti, Giovanni
dc.contributor.authorDi Carlo, Francesco
dc.contributor.authorMiuli, Andrea
dc.contributor.authorDattoli, Luigi
dc.contributor.authorPettorruso, Mauro
dc.contributor.authorDi Giannantonio, Massimo
dc.date.accessioned2022-01-31T10:30:05Z
dc.date.available2022-01-31T10:30:05Z
dc.date.issued2022-01-27
dc.identifier.citationChiappini , S , Mosca , A , Martinotti , G , Di Carlo , F , Miuli , A , Dattoli , L , Pettorruso , M & Di Giannantonio , M 2022 , ' Brexpiprazole as a new approach of treatment in somatization disorder ' , Emerging Trends in Drugs, Addictions and Health , vol. 2 , 100031 . https://doi.org/10.1016/j.etdah.2022.100031
dc.identifier.issn2667-1182
dc.identifier.otherPURE: 26744124
dc.identifier.otherPURE UUID: 5c4d6c47-da6f-46a4-8073-ae363fef30de
dc.identifier.otherJisc: 0f00308b0c074365a81d982a95ffc3f8
dc.identifier.urihttp://hdl.handle.net/2299/25339
dc.description© 2022 Published by Elsevier Ltd on behalf of International Society for the Study of Emerging Drugs. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
dc.description.abstractIntroduction: Somatic symptom disorder (SSD) is a mental disorder that involves one or more physical symptoms (e.g. palpitations, dizziness, diarrhoea, limb weakness, pain, and pseudo neurological symptoms) accompanied by one or more thoughts, feelings, and/or behaviours related to the somatic symptom(s) resulting in significant distress and/or dysfunction lasting for more than 6 months. At now the SSD can be refractory to psychiatric intervention including antidepressants, antiepileptics, and antipsychotics as well as the effectiveness of many of these treatments is limited. The objective of this study was to report the effectiveness of a third-generation antipsychotic drug brexpiprazole for treatment of a case of SSD together with the serotonin selective reuptake inhibitor (SSRI) fluvoxamine. Methods: A single case study of a 59-year-old female with SSD was here performed. Findings: After 4 weeks of treatment brexpiprazole, together with lamotrigine and fluvoxamine, was here effective in decreasing both depressive and anxiety symptoms, normalising previous unusual thought contents and of related behaviours. The patient reported an overall good response and started to function again in important domains of life. No adverse events occurred. Conclusion: To our knowledge, this is the first case showing Brexpiprazole effective for the treatment of a case of SSD as add-on to other drugs.en
dc.format.extent5
dc.language.isoeng
dc.relation.ispartofEmerging Trends in Drugs, Addictions and Health
dc.rightsOpen
dc.titleBrexpiprazole as a new approach of treatment in somatization disorderen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dc.description.versiontypeFinal Published version
dcterms.dateAccepted2022-01-27
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.etdah.2022.100031
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeOpen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record